Effects of tobacco on antipsychotic treatments and their extrapyramidal symptoms in schizophrenia
Keywords:
Schizophrenia, Antipsychotics, TobaccoAbstract
Background: The prevalence of cigarette smoking is significantly higher among patients with schizophrenia than in the general population. Several authors explained this excess of smoking by the self-medication hypothesis. It suggests that patients with schizophrenia smoke to reduce psychotic symptoms or antipsychotic side effects.Aim: In this study, we aimed to evaluate the prevalence of tobacco consumption in patients with schizophrenia and to test if smoking reduces psychotic and extra-pyramidal symptoms.
Methods: We included 115 patients with schizophrenia (DSM IV) treated with conventional antipsychotics. We assessed psychotic symptoms with the Positive and Negative Syndrome Scale (PANSS) and extrapyramidal symptoms with the Simpson-Angus scale.
Results: Prevalence of smoking was 60% (80% in men and 22.5% in women). The majority of them started their consumption before their illness. Smokers and non-smokers had similar rates of psychotic and extrapyramidal symptoms with comparable doses of antipsychotics and anticholinergic agents which were prescribed for similar durations.
Conclusion: In this study, patients with schizophrenia smoke a lot for reasons other than reducing psychotic or extrapyramidal symptoms.
Downloads
References
Dervaux A, Laqueille X. Tabac et schizophrénie: aspects épidémiologiques et cliniques. L'Encéphale 2008; 34: 299-305.
De Leon J, Diaz FJ. A meta-analysis of world wide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr Res 2005; 76:135-57.
Laqueille X, Ghodbane S, Nacef F et al. Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia. Schizophr Res 2008; 98: 327-8.
Fakhfakh R, Hsairi M, Maalej M. Tobacco use in schizophrenia: behaviour and awareness. Bull World Health Organ 2002; 80:350-6.
Kumari And Postma. Nicotine use in schizophrenia: the self medication hypothesis. Neurosci Biobehav Rev 2005; 29: 1021-34.
Atkins M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin 1997; 21: 224-6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC, USA, 1994.
De Leon J. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophr Res 2006; 86: 256-68.
Kay Sr, Fiszbein A, Opler LA. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizphr Bull 1987; 13: 261-76.
Lejoyeux M, Gorwood P, Stalla-Bourdillon A, ADES J. Traduction et utilisation de l'échelle de Simpson et Angus de symptômes extrapyramidaux. L'Encéphale 1993, 19: 17-21.
Goff Dc, Henderson Dc, Amico O. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189-94.
Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70: 193-7.
Chong Sa, Choo HL. Smoking among Chinese patients with schizophrenia. Aust N Z J Psychiatry 1996; 30: 350-3.
Kelly C. Cigarette smoking and schizophrenia. Adv Psych Treat 2000; 6: 327-31.
Barnes M, Lawford Br, Burton SC et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry 2006; 40: 575-80.
Levander S, Eberhard J, Lindström E. Nicotine use and its correlates in patients with psychosis. Acta psychiatr scand 2007; 435:27-32.
Ziedonis Dm, Kosten Tr, Glazer Wm, Frances RJ. Nicotine dependance and schizophrenia. Hosp Community Psychiatr 1994; 45: 204-6.
Zhang Xy, Tan Yl, Zhou Df Et AL. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacol 2007; 32: 2020-4.
Iancu I, Sapir Ap, Shaked G et al. Increased suicidal risk among smoking schizophrenia patients. Clin Neuropharmacol 2006; 29: 230-7.
Decina P. Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry 1990; 28: 502-8.
Poirier Mf, Canceil O, Baylé F Et AL. Prevalence of smoking in psychiatric patients. Prog Neuro-psychopharmacol Biol Psychiatry 2002; 26: 529-37.
Jabs BE. Susceptibility to neuroleptic-induced Parkinsonism age and increased substantia nigra echogenicity as putative risk factors. Europ Psychiatry 2003; 18: 177-81.
Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinisea. Biol Psychiatry 1987; 22: 67-72.
Wagner B, Wolf G, Ulmar G. Does smoking reduce the risk of neuroleptic Parkinoism? Pharmacopsychiatry 1988; 21: 302-3.
Menza Ma, Grossman N, Van Horn M, Cody R, Forman R. Smoking and movement disorders in schizophrenia patients. Biol Psychiatry 1991; 30:109-55.
Aguilar C, Gurpegui M, Diaz F, De Leon J. Nicotine dependence and symptoms in schizophrenia Naturalistic study of complex interactions. BJ Psychiatry 2005; 186: 215-21.
Addington J, El-Guebaly N, Campbell W, Hodgins Dc, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998; 155:974-6.
Dalack W, Healy D, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155:1490-1501.
Evins Ae, Deckersbach T, Cather C et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005; 66:1184-90.
Fatemi Sh, Stary Jm, Hatsukami Dk, Murphy SE. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res 2005; 76: 353-6.
Dalak Gw, Becks L, Hill E et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacol 1999; 21:195-202.
Leonard S, Giordano L. Differential behavioral responses to smoking and smoking cessation in schizophrenia related to nicotinic receptor levels? Neuropsychopharmacol 2002; 27:1082-3.
